Skip to main content
. 2014 Nov;99(11):1697–1700. doi: 10.3324/haematol.2014.109249

Figure 1.

Figure 1.

Survival of 309 subjects with PMF classified by CALR, JAK2, MPL or no detectable mutation. (A) CALR type-1 vs. -2 vs. JAK2 vs. MPL vs. no detectable mutation; (P<0.001); (B) CALR type-2 or no detectable mutation vs. JAK2, MPL, CALR type-1 and infrequent CALR mutation (referred to other mutations, P<0.001).